Deficient counterregulatory hormone responses during hypoglycemia in a patient with insulinoma

Maris R. Davis, Harry Shamoon

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Counterregulatory hormone responses were evaluated in a 37-yr-old woman before and after removal of a benign insulin-producing islet cell tumor. Counterregulatory hormone concentrations were measured during a glucose clamp with graded reductions of plasma glucose from 5.2 to 2.6 mmol/ L. In the study before surgery, the increase in plasma epinephrine concentration was markedly blunted (by >90%) compared to that in the study after surgery. The peak plasma norepinephrine concentration was similarly reduced by 71%, and plasma Cortisol by 63%. In addition, the glycemic thresholds for secretion of the counterregulatory hormones were lower before removal of the tumor. Peak plasma GH responses were equivalent before and after surgery, but the threshold for GH secretion was 21% lower in the first hypoglycemia study. We conclude 1) that there is evidence for abnormal glucose counterregulatory hormone secretion in this patient, which may contribute to the pathogenesis of hypoglycemia seen in patients with insulinoma; 2) the reversal of reduced counterregulatory hormone secretion after tumor resection suggests that these defective hormonal responses may be related to recurrent hypoglycemia, persistent hyperinsulinemia, or both; and 3) that abnormal glucose counterregulation may exist in the absence of type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)788-792
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume72
Issue number4
StatePublished - Apr 1991

Fingerprint

Insulinoma
Hypoglycemia
Hormones
Plasmas
Surgery
Glucose
Tumors
Islet Cell Adenoma
Glucose Clamp Technique
Clamping devices
Hyperinsulinism
Medical problems
Type 1 Diabetes Mellitus
Epinephrine
Hydrocortisone
Neoplasms
Norepinephrine
Insulin

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Deficient counterregulatory hormone responses during hypoglycemia in a patient with insulinoma. / Davis, Maris R.; Shamoon, Harry.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 72, No. 4, 04.1991, p. 788-792.

Research output: Contribution to journalArticle

@article{40867207d9ca42d4958e968caaa967e5,
title = "Deficient counterregulatory hormone responses during hypoglycemia in a patient with insulinoma",
abstract = "Counterregulatory hormone responses were evaluated in a 37-yr-old woman before and after removal of a benign insulin-producing islet cell tumor. Counterregulatory hormone concentrations were measured during a glucose clamp with graded reductions of plasma glucose from 5.2 to 2.6 mmol/ L. In the study before surgery, the increase in plasma epinephrine concentration was markedly blunted (by >90{\%}) compared to that in the study after surgery. The peak plasma norepinephrine concentration was similarly reduced by 71{\%}, and plasma Cortisol by 63{\%}. In addition, the glycemic thresholds for secretion of the counterregulatory hormones were lower before removal of the tumor. Peak plasma GH responses were equivalent before and after surgery, but the threshold for GH secretion was 21{\%} lower in the first hypoglycemia study. We conclude 1) that there is evidence for abnormal glucose counterregulatory hormone secretion in this patient, which may contribute to the pathogenesis of hypoglycemia seen in patients with insulinoma; 2) the reversal of reduced counterregulatory hormone secretion after tumor resection suggests that these defective hormonal responses may be related to recurrent hypoglycemia, persistent hyperinsulinemia, or both; and 3) that abnormal glucose counterregulation may exist in the absence of type 1 diabetes.",
author = "Davis, {Maris R.} and Harry Shamoon",
year = "1991",
month = "4",
language = "English (US)",
volume = "72",
pages = "788--792",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Deficient counterregulatory hormone responses during hypoglycemia in a patient with insulinoma

AU - Davis, Maris R.

AU - Shamoon, Harry

PY - 1991/4

Y1 - 1991/4

N2 - Counterregulatory hormone responses were evaluated in a 37-yr-old woman before and after removal of a benign insulin-producing islet cell tumor. Counterregulatory hormone concentrations were measured during a glucose clamp with graded reductions of plasma glucose from 5.2 to 2.6 mmol/ L. In the study before surgery, the increase in plasma epinephrine concentration was markedly blunted (by >90%) compared to that in the study after surgery. The peak plasma norepinephrine concentration was similarly reduced by 71%, and plasma Cortisol by 63%. In addition, the glycemic thresholds for secretion of the counterregulatory hormones were lower before removal of the tumor. Peak plasma GH responses were equivalent before and after surgery, but the threshold for GH secretion was 21% lower in the first hypoglycemia study. We conclude 1) that there is evidence for abnormal glucose counterregulatory hormone secretion in this patient, which may contribute to the pathogenesis of hypoglycemia seen in patients with insulinoma; 2) the reversal of reduced counterregulatory hormone secretion after tumor resection suggests that these defective hormonal responses may be related to recurrent hypoglycemia, persistent hyperinsulinemia, or both; and 3) that abnormal glucose counterregulation may exist in the absence of type 1 diabetes.

AB - Counterregulatory hormone responses were evaluated in a 37-yr-old woman before and after removal of a benign insulin-producing islet cell tumor. Counterregulatory hormone concentrations were measured during a glucose clamp with graded reductions of plasma glucose from 5.2 to 2.6 mmol/ L. In the study before surgery, the increase in plasma epinephrine concentration was markedly blunted (by >90%) compared to that in the study after surgery. The peak plasma norepinephrine concentration was similarly reduced by 71%, and plasma Cortisol by 63%. In addition, the glycemic thresholds for secretion of the counterregulatory hormones were lower before removal of the tumor. Peak plasma GH responses were equivalent before and after surgery, but the threshold for GH secretion was 21% lower in the first hypoglycemia study. We conclude 1) that there is evidence for abnormal glucose counterregulatory hormone secretion in this patient, which may contribute to the pathogenesis of hypoglycemia seen in patients with insulinoma; 2) the reversal of reduced counterregulatory hormone secretion after tumor resection suggests that these defective hormonal responses may be related to recurrent hypoglycemia, persistent hyperinsulinemia, or both; and 3) that abnormal glucose counterregulation may exist in the absence of type 1 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0025798613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025798613&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 788

EP - 792

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -